https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct02858921-2026-08-24 Hipa.ai en 2026-08-24T00:00:00.000Z Pembrolizumab trial posts response counts in melanoma https://hipa.ai/drug/semaglutide/updates/trial-results-posted-nct04596631-2026-08-21 Hipa.ai en 2026-08-21T00:00:00.000Z Semaglutide trial shows HbA1c improvement in youth with type 2 diabetes https://hipa.ai/drug/canagliflozin/updates/boxed-warning-revised-metformin-hydrochloride-label-2026-08-21 Hipa.ai en 2026-08-21T00:00:00.000Z Canagliflozin Label Cites Revised Metformin Boxed Warning https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-actoplus-met-label-effective-2026-08-21 Hipa.ai en 2026-08-21T00:00:00.000Z Canagliflozin: Actoplus Met Label Carries Boxed Warning https://hipa.ai/drug/mavacamten/updates/trial-results-posted-nct05582395-2026-08-20 Hipa.ai en 2026-08-20T00:00:00.000Z Mavacamten Trial Shows Mixed Results in Non-Obstructive HCM https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct03274258-2026-08-20 Hipa.ai en 2026-08-20T00:00:00.000Z Nivolumab Trial in Renal Medullary Carcinoma Reports No Responses https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-metformin-hydrochloride-label-2026-08-20 Hipa.ai en 2026-08-20T00:00:00.000Z Canagliflozin: Metformin Label Carries Boxed Warning https://hipa.ai/drug/inclisiran/updates/indication-usage-updated-leqvio-label-effective-2026-08-19-2026-08-19 Hipa.ai en 2026-08-19T00:00:00.000Z Inclisiran label adds adults and adolescents aged 12 and older https://hipa.ai/drug/evolocumab/updates/indication-usage-updated-repatha-label-effective-2026-08-19-2026-08-19 Hipa.ai en 2026-08-19T00:00:00.000Z Repatha Label Revision Changes Indications and Usage